Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Disruptions in estrogen exposure (i.e., surgically induced menopause) have been linked to poorer cognitive aging and dementia risk. Hormone therapy use (e.g., birth control, menopausal hormone therapy) has shown mixed associations with cognitive performance, possibly due to limited cognitive test batteries. To address previous inconsistencies, we investigated baseline data from Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE). We hypothesized that (1) oophorectomy prior to natural menopause would be associated with poorer cognitive performance, (2) timing and duration of birth control and menopausal hormone therapy would influence associations with cognitive performance, and (3) carrier status would interact with oophorectomy and hormone therapy to influence cognitive performance.

Methods: In 461 post-menopausal females (M age = 69.6) we assessed oophorectomy and hormone therapy use to examine associations with the Montreal Cognitive Assessment (MoCA) and factor-analytically derived composite scores for episodic memory, processing speed, working memory, executive function/attentional control, and visuospatial processing.

Results: Hypothesis (1) We did not observe associations between oophorectomy prior to natural menopause and poorer cognitive performance. However, hormone therapy use, started on average within 2 years of oophorectomy, was associated with better episodic memory (β = 0.106, = 0.02), working memory (β = 0.120, = 0.005), and visuospatial processing (β = 0.095, = 0.03). Hypothesis (2) Birth control use was associated with better performance on the MoCA (β = 0.093, = 0.04), working memory (β = 0.102, = 0.02), and executive function/attentional control (β = 0.103, = 0.02). However, duration and timing of birth control and menopausal hormone therapy were not associated with cognitive performance. Hypothesis (3) We did not observe significant interactions between status and oophorectomy or hormone therapy in their associations with cognitive performance.

Discussion: Our results suggest exposure to estrogen during adulthood, specifically birth control and hormone therapy among women undergoing pre-menopausal oophorectomy, benefits cognitive function in older adulthood. Our comprehensive cognitive battery allowed us to examine cognitive function with a high degree of granularity. Future work should evaluate causal mechanisms of associations between lifetime estrogen exposure and later life cognitive function.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003372PMC
http://dx.doi.org/10.3389/fnagi.2025.1524474DOI Listing

Publication Analysis

Top Keywords

hormone therapy
36
cognitive performance
24
birth control
20
cognitive
15
estrogen exposure
12
poorer cognitive
12
control menopausal
12
menopausal hormone
12
associations cognitive
12
oophorectomy hormone
12

Similar Publications

Medical treatment of fibroids: FIGO best practice guidance.

Int J Gynaecol Obstet

September 2025

Department of Gynecology and Obstetrics, Justus Liebig University Giessen, Giessen, Germany.

Even though uterine fibroids are a widespread condition, the range of approved medical treatment options remains limited. In fact, only a few drugs are officially approved for the therapy of fibroids. In both the USA and the European Medicines Agency region, selected gonadotropin-releasing hormone (GnRH) antagonists have been approved for this indication.

View Article and Find Full Text PDF

Using longitudinal national prescribing data, we estimated the number of transgender and gender-diverse individuals initiating gender-affirming hormone therapy (GAHT) from 2013 to 2024 in Australia. Between 2013 and 2024, 11 883 individuals initiated testosterone-based GAHT and 20 358 initiated oestrogen-based GAHT. Initiation rose from 1118 in 2013 to 5135 in 2024, with a growing share accessing testosterone-based GAHT over time.

View Article and Find Full Text PDF

The Oncotype DX test is standardly used for patients with early-stage, hormone-receptor-positive, HER2-negative breast cancers to determine the benefit from chemotherapy and the likelihood of distant recurrence. The relationship between Oncotype DX recurrence scores and race/ethnicity is still being studied. This retrospective study aims to evaluate the relationship between Oncotype DX recurrence scores, race/ethnicity, and clinicopathological factors and to support the applicability of the Oncotype DX test for a diverse breast cancer population of Hawaii.

View Article and Find Full Text PDF

Pregnancy after breast cancer treatment in young patients.

Front Oncol

August 2025

Department of Surgery, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Republic of Korea.

Introduction: Breast cancer (BC) treatments can impair fertility in young women, causing considerable distress and potentially influencing treatment decisions, yet comprehensive real-world data on pregnancy outcomes after BC remain limited. This study aims to provide comprehensive real-world data on pregnancy following BC treatment to guide clinical practice and patient counseling.

Methods: We conducted a retrospective cohort study using medical records from a single tertiary medical center in South Korea.

View Article and Find Full Text PDF

Tuberous breast deformity in a transgender woman: a case report.

J Surg Case Rep

September 2025

Division of Plastic and Reconstructive Surgery, University of California, Los Angeles, 200 Medical Plaza, Suite 460, Los Angeles, CA 90095, United States.

Tuberous breast deformity was first documented by Rees and Aston in 1976. The deformity is well documented in cisgender women, with rare cases in cisgender men often associated with gynecomastia, and almost no reports in transgender women. Herein, we present a case of a 32-year-old transgender woman who developed bilateral tuberous breast deformity after 10 years of hormone replacement therapy.

View Article and Find Full Text PDF